Olink Holding AB (publ) provides various products and services for the academic, government, biopharmaceutical, biotechnology, and other institutions that focuses on life science research. Its products include Olink Explore for cardiovascular and metabolic, oncology, neurology, or inflammation diseases; Olink Target product line; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on. The company's products also comprise Olink Signature Q100, a qPCR readout platform; Olink Analysis services comprising study design and consultation, sample preparation and assay execution, and data processing and QC; and bioinformatics services. In addition, it provides Olink normalized protein expression (NPX) Manager, a purpose-built software that enable users to import data, validate data quality, and normalize for subsequent statistical analysis; and Olink Insight, a cloud platform for data visualization and statistical analysis of NPX data. Olink Holding AB (publ) sells its products and services through its own direct sales force in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Knilo HoldCo AB and changed its name to Olink Holding AB (publ) in January 2021. The company was founded in 2004 and is headquartered in Uppsala, Sweden. Olink Holding AB (publ) is a subsidiary of Summa Equity Holding AB.

Olink Holding AB (publ)

Olink offers an unmatched high-multiplex technique to identify actionable biomarkers, with a strong focus on the human plasma proteome. Using minimal sample volume we provide quantifiable results with high-throughput, exceptional sensitivity and specificity, with coverage across a broad dynamic range. Our mission is to accelerate proteomics together with the scientific community across multiple disease areas to enable new discoveries and better understand complex real-time human biology. We are committed to develop our offering and are continuously expanding our protein coverage for a growing number of biological processes and pathways.
 
Olink is well-established in Europe (HQ Uppsala, Sweden) and the USA (HQ Boston, MA), with a rapidly developing presence across Asia. We also work with a growing number of core labs around the world offering analysis and support to an expanding global customer base.
 
For more information visit www.olink.com

Olink Proteomics

Touchdown in London! We're eager to discuss proteomics with you at the Festival of Genomics!

Swing by Booth #109 to discover how integrating genomics and proteomics helps reveal novel drug targets and new insights into disease pathways. Plus, don't miss your chance to see our Signature Q100 instrument in action!

We're looking forward to sharing ideas and learning together. Come and join the conversation!

#Olink #Proteomics #FOG2024



Will in-depth proteome profiling using self-sampled blood be the next step in monitoring individual health status in the era of precision medicine? Let’s hear the most recent progress in this topic from Professor Jochen M Schwenk (Royal Institute of Technology, Sweden) and discuss the challenges together in the session on Disease Proteomics at 29th Annual Lorne Proteomics Symposium on Feb 2, 2024, at Lorne, Australia!  

Check out the full symposium program at
https://bit.ly/3RMSubI 
#Proteomics #LorneProteomicsSymposium #Australia

We are thrilled to kick off the new year of events and connecting in person with you as our AMER team gears up for their first event of 2024 – PMWC (Precision Medicine World Conference)!
 
From our start, our mission has been to achieve the goal of precision medicine and individualized healthcare through the advancement of protein biomarker discovery and analysis. This future can only be realized with the collaboration of the scientific community so we are thrilled to connect with you at PMWC 2024 and the many events our teams will be attending. Stay tuned for updates as our team engages in insightful discussions and seeks to contribute to the future of healthcare.
 
Here's to a year filled with innovation, learning, and impactful connections! Let's make 2024 a year to remember! 🎉 

#PMWC2024 #precisionmedicine #olink

Extracting new insights from your genomics data? Discovering novel drug targets?
 
We're excited to share the power of proteomics with you at the Festival of Genomics & Biodata in London on Jan 24-25, 2024!
 
From biobank studies to disease-focused research, proteomics can empower your genomics projects and help you understand real-time human biology and overcome drug development challenges.
 
Come meet us at Booth #109 to discover how proteomics can complement your genomics studies and see our Signature Q100 instrument in action.
 
#Olink #Proteomics #FOG2024

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	41.69M -	54.07M 29.68%	94.97M 75.66%	139.85M 47.25%	169.91M 21.49%
cost of revenue	13.02M -	17.46M 34.09%	36.76M 110.60%	45.35M 23.36%	71.04M 56.64%
gross profit	28.68M -	36.61M 27.68%	58.21M 59.00%	94.50M 62.34%	98.87M 4.63%
selling and marketing expenses	8.25M -	12.72M 54.26%	33.67M 164.64%	44.67M 32.69%	12.24M 72.61%
general and administrative expenses	26.61M -	20.10M 24.45%	47.49M 136.27%	54.27M 14.27%	105.79M 94.92%
selling general and administrative expenses	34.86M -	32.82M 5.83%	81.16M 147.27%	98.95M 21.91%	118.25M 19.50%
research and development expenses	4.84M -	9.63M 98.80%	22.14M 129.87%	26.34M 18.99%	30.57M 16.02%
other expenses	-363K -	-475K 30.85%	-443K 6.74%	-191K 56.88%
cost and expenses	52.36M -	59.44M 13.52%	139.62M 134.91%	170.45M 22.08%	219.85M 28.98%
operating expenses	39.34M -	41.98M 6.72%	102.86M 145.02%	125.10M 21.62%	148.81M 18.95%
interest expense	6.60M -	6.63M 0.48%	2.05M 69.11%	531K 74.07%	858K 61.58%
ebitda	-2.79M -	6.46M 331.27%	-30.57M 573.44%	-11.61M 62.02%	-30.91M 166.22%
operating income	-10.66M -	-6.08M 42.95%	-44.65M 634.05%	-30.60M 31.47%	-49.94M 63.19%
depreciation and amortization	7.87M -	12.54M 59.32%	14.08M 12.30%	18.99M 34.87%	19.03M 0.22%
total other income expenses net	-7.87M -	-1.18M 85.05%	-1.89M 60.97%	15.20M 902.69%	9.96M 34.44%
income before tax	-18.53M -	-7.26M 60.83%	-46.55M 541.20%	-15.41M 66.90%	-39.98M 159.48%
income tax expense	-652K -	-479K 26.53%	-8.21M 1,613.15%	-2.56M 68.85%	-8.32M 225.52%
net income	-17.88M -	-6.78M 62.08%	-38.34M 465.47%	-12.85M 66.48%	-31.66M 146.34%
weighted average shs out	119.01M -	105.77M 11.12%	99.26M 6.16%	119.01M 19.89%	124.00M 4.20%
weighted average shs out dil	119.01M -	105.77M 11.12%	99.26M 6.16%	119.01M 19.89%	124.00M 4.20%
eps	-0.15 -	-0.06 57.27%	-0.39 508.42%	-0.11 71.79%	-0.26 136.36%
epsdiluted	-0.15 -	-0.06 57.27%	-0.39 508.42%	-0.11 71.79%	-0.26 136.36%

COM:OLINK

Olink Holding AB

Last Close

26.00

09/07 20:00

Market Cap

3.24B

Beta: -

Volume Today

1.89M

Avg: -

Preview